We synthesized an estrogen analog, ZYC-5, lacking activity at the classical estrogen receptor and examined its neuroprotective potential against necrosis induced by N-methyl-D-aspartate (NMDA) and apoptosis/necrosis induced by the NMDA receptor antagonist (؉)-3-(2-carboxypiperazine-4-yl )-propyl-1-phosphonic acid (CPP). ZYC-5 protected cortical neurons in a dose-dependent manner, and the neuroprotection was more robust than with 17␤-estradiol. The effect of ZYC-5 was not mediated by the classical estrogen receptor, because it was unaffected by the antagonists 4-hydroxytamoxifen and ICI 182,780. The ZYC-5 protection against excitotoxicity was not directly mediated through the NMDA receptor, because there was no effect of ZYC-5 on NMDA current or the intracellular calcium increase induced by NMDA. Results obtained with the free-radical-sensitive dye, dihydroethidium, suggested that the neuroprotection of ZYC-5 was partly related to its radical scavenging properties. Although some of estrogen's neuroprotective effects may depend upon the estrogen receptor, our results suggest the possibility of neuroprotection without hormonal side effects. © 2002 Elsevier Science (USA)
Estrogens are important for the differentiation of specific hypothalamic nuclei, and an increasingly large body of evidence suggests that estrogens may also be important for normal brain function. Differences in estrogen levels may account for sexual disparities in the incidence of several common neurological diseases (Beyer, 1999; Shughrue and Merchenthaler, 2000) . For example, epidemiological studies have indicated that the incidence and prevalence of Parkinson's disease is higher in men than in women (Mayeux et al., 1995; Blanchet et al., 1999) . There are studies showing that the decline of serum estrogen concentration is related to the risk of Alzheimer's disease in postmenopausal women and that estrogen replacement therapy may reduce the morbidity of this disease (Tang et al., 1996; Henderson, 1997; Birge, 1997; Benson, 1999) . Estrogen exposure may also decrease the neuronal damage from stroke in humans (Hurn and Macrae, 2000) .
Although a number of factors may account for the clinical benefits of estrogens, recent studies support the hypothesis that estrogens have a direct protective action on neurons (Behl and Holsboer, 1999; Green and Simpkins, 2000; Garcia-Segura et al., 2001 ). Estrogen-mediated neuroprotection has been described in several in vitro models of neurodegeneration, including serum-deprivation, ␤-amyloid-induced toxicity, excitotoxicity, and oxidative stress (Behl et al., 1995; Goodman et al., 1996; Green et al., 1997a; Regan and Guo, 1997; Gollapudi and Oblinger, 1999; Bae et al., 2000) . The effective concentration for 17␤-estradiolmediated neuroprotection ranges from 0.1 nM to 50 M, suggesting that a variety of mechanisms may contribute (Brinton et al., 1997; Green et al., 1997a; Sawada et al., 1998; Bae et al., 2000) . These possible
